Laser nanobubbles induce immunogenic cell death in breast cancer

Nguyen, Hieu T. M.; Katta, Nitesh; Widman, Jessica A.; Takematsu, Eri; Feng, Xu; Torres-Hurtado, S. A.; Betancourt, Tania; Baker, Aaron; Suggs, Laura J.; Milner, Thomas E.; Tunnell, James W.

doi:10.1039/d0nr06587k

Cited by 9 publications

(5 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…some protease-related inhibitors [26][27][28][29][30][31] and metal complexes. [32][33][34][35] After administration of ICD inducers, four phases can be used briefly to succinctly characterize the ICD process: 1) ICD inducers enter tumor tissue and taken up by tumor cells; 2) endoplasmic reticulum stress, oxidative stress and other responses occur within tumor cells to result the release of DAMPs; 3) antigenpresenting cells (APCs) are recruited and activated by the DAMPs and perform antigen presentation to naive T cells; and 4) the differentiation and maturation of naive T cells catalyzed by APCs, which recognize and kill tumor cells in a long-term immune memory manner. [10] Based on the above processes of ICD, we have summarized the nanoparticles for enhancing ICD in recent years according to the nanotechnologies in reinforcement of each process of ICD.…”

Section: Immunogenic Cell Deathmentioning

confidence: 99%

Promotion of ICD via Nanotechnology

Qin

Zhang

et al. 2023

Macromolecular Bioscience

View full text Add to dashboard Cite

Immunotherapy represents the most promising treatment strategy for cancer, but suffers from compromised therapeutic efficiency due to low immune activity of tumor cells and an immunosuppressive microenvironment, which significantly hampers the clinical translations of this treatment strategy. To promote immunotherapy with desired therapeutic efficiency, immunogenic cell death (ICD), a particular type of death capable of reshaping body's antitumor immune activity, has drawn considerable attention due to the potential to stimulate a potent immune response. Still, the potential of ICD effect remains unsatisfactory because of the intricate tumor microenvironment and multiple drawbacks of the used inducing agents. ICD has been thoroughly reviewed so far with a general classification of ICD as a kind of immunotherapy strategy and repeated discussion of the related mechanism. However, there are no published reviews, to the authors’ knowledge, providing a systematic summarization on the enhancement of ICD via nanotechnology. For this purpose, this review first discusses the four stages of ICD according to the development mechanisms, followed by a comprehensive description on the use of nanotechnology to enhance ICD in the corresponding four stages. The challenges of ICD inducers and possible solutions are finally summarized for future ICD‐based enhanced immunotherapy.

show abstract

Section: Immunogenic Cell Deathmentioning

confidence: 99%

Promotion of ICD via Nanotechnology

Qin

Zhang

et al. 2023

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…This approach enables the evaluation of both traditional and innovative combinational cancer nanotherapies. 91,104 Recent findings highlight an elevated expression of stromal galectin-1 in clinical TNBC samples. Ongoing research explores stromal targeting of radiation-induced galectin-1 using anginexconjugated arsenic-cisplatin-loaded liposomes.…”

Section: Micellesmentioning

confidence: 99%

Enhancing Breast Cancer Therapy: Nanocarrier-Based Targeted Drug Delivery

Pandey,

Dhiman,

Bazad

et al. 2023

Preprint

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most common types of cancer in women. Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), exhibits a highly aggressive phenotype with increased metastasis and resistance to conventional treatments. Nanocarrier technology is consistently employed to overcome limitations associated with traditional breast cancer therapy. The targeted drug delivery approach using nanocarriers enhances bioavailability, prolongs circulation, and facilitates effective drug accumulation at the tumor site through active or passive targeting. Currently, the FDA has approved a few nanocarrier systems, and numerous nano formulations are undergoing preclinical and clinical development for breast cancer targeting. Common nanocarrier types include polymeric micelles, microemulsions, magnetic microemulsions, liposomes, dendrimers, carbon nanotubes, and magnetic nanoparticles (NPs). This review extensively explores the targeting potential of nanocarriers in breast cancer. This study will provide a concise summary of current advances in treatment of breast cancer and diagnostics.

show abstract

“…The effect of NPS resulted in a significant reduction of immunosuppressive cells such as Tregs, DC maturation and activation, massive death of tumor cells, enhanced antitumor immune effects, and inhibition of distant metastases. NPS is another application of nanotechnology, as a highly efficacious inducer of ICD, and its unique therapeutic advantages provide a new option for nanotechnological tumor treatment ( 194 , 218 , 219 ).…”

Section: New Techniques For Icd Inductionmentioning

confidence: 99%

Research progress in inducing immunogenic cell death of tumor cells

Xie

Wang

2022

Front. Immunol.

View full text Add to dashboard Cite

Immunogenic cell death (ICD) is a regulated cell death (RCD) pathway. In response to physical and chemical signals, tumor cells activate specific signaling pathways that stimulate stress responses in the endoplasmic reticulum (ER) and expose damage-associated molecular patterns (DAMPs), which promote antitumor immune responses. As a result, the tumor microenvironment is altered, and many tumor cells are killed. The ICD response in tumor cells requires inducers. These inducers can be from different sources and contribute to the development of the ICD either indirectly or directly. The combination of ICD inducers with other tumor treatments further enhances the immune response in tumor cells, and more tumor cells are killed; however, it also produces side effects of varying severity. New induction methods based on nanotechnology improve the antitumor ability and significantly reduces side effects because they can target tumor cells precisely. In this review, we introduce the characteristics and mechanisms of ICD responses in tumor cells and the DAMPs associated with ICD responses, summarize the current methods of inducing ICD response in tumor cells in five distinct categories: chemical sources, physical sources, pathogenic sources, combination therapies, and innovative therapies. At the same time, we introduce the limitations of current ICD inducers and make a summary of the use of ICD responses in clinical trials. Finally, we provide an outlook on the future of ICD inducer development and provide some constructive suggestions.

show abstract

Laser nanobubbles induce immunogenic cell death in breast cancer

Abstract: Laser nanobubbles induce dendritic cell activation in breast cancer cells.

Cited by 9 publications

References 53 publications

Promotion of ICD via Nanotechnology

Promotion of ICD via Nanotechnology

Enhancing Breast Cancer Therapy: Nanocarrier-Based Targeted Drug Delivery

Research progress in inducing immunogenic cell death of tumor cells

Contact Info

Product

Resources

About